Cardiology medical device company AtriCure (NASDAQ:ATRC) is aiming to begin in the fourth quarter a clinical trial investigating its AtriClip device in the treatment of stroke patients. Before that can happen, though, the Cincinnati-area company must complete development of a next-generation version of the AtriClip, a device used to exclude the left atrial appendage during […]
AtriCure (Nasdaq:ATRC) CEO David Drachman’s compensation package received a 64 percent boost to $1.9 million last year. The Cincinnati-based cardiac devicemaker paid Drachman about $1.5 million in stock and options and $450,000 in salary in 2011, according to a proxy statement AtriCure filed today. Drachman’s salary in 2010 was $412,000, with a total compensation of […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
With a key FDA approval in hand for its cardiac ablation technology, device maker AtriCure (NASDAQ:ATRC) has its sights set on grabbing market share from industry giant Medtronic (NYSE:MDT). In December, AtriCure’s Synergy ablation system became the first medical device to receive U.S. Food and Drug Administration approval for the surgical treatment of atrial fibrillation […]
Cardiology medical device company AtriCure (NASDAQ:ATRC) has received U.S. Food and Drug Administration approval for a stroke safety and feasibility trial of its AtriClip device. The trial will enroll up to 30 patients at six sites and begin enrollment in the second half of 2012, CEO Dave Drachman said earlier this week in a conference […]
Late last year, an ablation system from cardiology device maker AtriCure (NASDAQ:ATRC) became the first device to secure U.S. Food and Drug Administration clearance for the surgical treatment of atrial fibrillation. Now, the Cincinnati-area company’s attention will turn to training surgeons to perform atrial fibrillation procedures using its device, the Synergy Ablation System. CEO David […]
Cardiac device company AtriCure (NASDAQ:ATRC) has again been identified by an equities analyst as a likely acquisition target for a big medical device firm. Barrington Research listed Cincinnati-area AtriCure as among its top 15 stock picks for the year and called the company a strong candidate for a buyout, the Cincinnati Business Courier reported. “ATRC […]
Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients. The Cincinnati-area company is planning next year to begin a clinical trial that will investigate the AtriClip for use in stand-alone procedures that involve exclusion of the left atrial appendage, a thumb-sized pouch on top […]
Cardiac device company AtriCure (NASDAQ:ATRC) has closed a feasibility clinical trial into a so-called “hybrid” procedure to treat atrial fibrillation, citing a change of plans in the study’s protocol. Cincinnati-area AtriCure’s DEEP AF feasibility study was investigating the hybrid procedure, which received that name because it combines catheter ablation, which occurs inside the heart, with […]
Cardiology devicemaker AtriCure (Nasdaq:ATRC) expects FDA approval of an atrial fibrillation label for a surgical ablation device in the first quarter of 2012. U.S. Food and Drug Administration approval of the atrial fibrillation (AF) label would make AtriCure the first company to have a device approved for the surgical treatment of AF and represent a […]
Shares of cardiac device maker AtriCure (NASDAQ:ATRC) jumped 20 percent after an FDA panel recommended approving one of the company’s device for the surgical treatment of atrial fibrillation. AtriCure shares climbed the most in 16 months to around $12 in Thursday afternoon trading as enthusiastic investors reacted to positive news about the company’s Synergy ablation […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Cardiac device maker AtriCure (NASDAQ:ATRC) saw its stock plunge Monday after an FDA report expressed “concerns” about a clinical trial for one of the company’s ablation devices. U.S. Food and Drug Administration staffers issued a (pdf) report in advance of an FDA advisory panel’s Wednesday meeting to review AtriCure’s application for approval of an atrial […]
Atrial fibrillation device company AtriCure (Nasdaq:ATRC) is among five medical companies most likely to be targeted for an acquisition in the next year, according to a new analyst report. In addition to Cincinnati-area AtriCure, the other device companies identified by Canaccord Genuity analyst Jason Mills as likely near-term acquisition targets were: HeartWare, Spectranetics, Thoratec and […]
A U.S. Food and Drug Administration panel will review cardiac device maker AtriCure‘s (NASDAQ:ATRC) application for a label for the surgical treatment of atrial fibrillation. On Oct. 26, the FDA’s Circulatory System Devices Panel will review the Cincinnati-area device maker’s Premarket Approval Application (PMA) for its Synergy ablation system, according to a statement from West […]
Medical device giants looking to boost their atrial fibrillation product portfolios would do well to take a long, hard look at cardiac device-maker AtriCure (NASDAQ:ATRC). Things have been looking up recently for Cincinnati-area AtriCure, and if the company hits a few near-term milestones its got in its sights, its price to a strategic acquirer will […]
Cardiology medical device maker AtriCure (NASDAQ:ATRC) expects to receive U.S. regulatory clearance for a new cryoablation system by the end of next quarter. The company’s cryoICE BOX system would use extreme cold to freeze cardiac tissue in order to correct abnormal electrical signals that cause heart arrhythmia. The system was launched during the second quarter […]
